Cargando…

Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme

PURPOSE: To report our results of image-guided interstitial (IRT) high-dose-rate (HDR) brachytherapy (BRT) in the primary treatment of patients with inoperable glioblastoma multiforme (GBM) in the pre-temozolomide period. MATERIAL AND METHODS: Between 1994 and 2004, 17 patients were treated with HDR...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatzikonstantinou, Georgios, Ulrich, Peter, Archavlis, Eleftherios, Zamboglou, Nikolaos, Strouthos, Iosif, Zoga, Eleni, Baltas, Dimos, Tselis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701379/
https://www.ncbi.nlm.nih.gov/pubmed/31435428
http://dx.doi.org/10.5114/jcb.2019.85722
_version_ 1783445045504901120
author Chatzikonstantinou, Georgios
Ulrich, Peter
Archavlis, Eleftherios
Zamboglou, Nikolaos
Strouthos, Iosif
Zoga, Eleni
Baltas, Dimos
Tselis, Nikolaos
author_facet Chatzikonstantinou, Georgios
Ulrich, Peter
Archavlis, Eleftherios
Zamboglou, Nikolaos
Strouthos, Iosif
Zoga, Eleni
Baltas, Dimos
Tselis, Nikolaos
author_sort Chatzikonstantinou, Georgios
collection PubMed
description PURPOSE: To report our results of image-guided interstitial (IRT) high-dose-rate (HDR) brachytherapy (BRT) in the primary treatment of patients with inoperable glioblastoma multiforme (GBM) in the pre-temozolomide period. MATERIAL AND METHODS: Between 1994 and 2004, 17 patients were treated with HDR BRT for inoperable GBM. Of those, only 11 patients were treated with IRT BRT, and the remaining six patients received combined IRT BRT and external beam radiotherapy (EBRT). Patient’s median age was 59.3 years (range, 29-83 years) and median tumor volume was 39.3 cm(3) (range, 2-162 cm(3)). The prescribed HDR dose was median 40 Gy (range, 30-40 Gy), delivered twice daily in 5.0 Gy fractions over four consecutive days. Survival from BRT, toxicity as well as the impact of several prognostic factors was evaluated. RESULTS: At a median follow-up of 9.3 months, the median overall survival for the whole population, after BRT alone, and combined BRT with EBRT was 9.3, 7.3, and 10.1 months, respectively. Of the prognostic variables evaluated in univariate analysis, i.e., age, Karnofsky performance score, BRT dose, and tumor volume, only the latter one reached statistical significance. Two patients (11.7%) developed treatment-associated adverse events, with one (5.8%) symptomatic radionecrosis and one (5.8%) severe convulsion episode, respectively. CONCLUSIONS: For patients with inoperable GBM, IRT HDR BRT alone or in combination with EBRT is a safe and effective irradiation method providing palliation without excessive toxicity.
format Online
Article
Text
id pubmed-6701379
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-67013792019-08-21 Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme Chatzikonstantinou, Georgios Ulrich, Peter Archavlis, Eleftherios Zamboglou, Nikolaos Strouthos, Iosif Zoga, Eleni Baltas, Dimos Tselis, Nikolaos J Contemp Brachytherapy Original Paper PURPOSE: To report our results of image-guided interstitial (IRT) high-dose-rate (HDR) brachytherapy (BRT) in the primary treatment of patients with inoperable glioblastoma multiforme (GBM) in the pre-temozolomide period. MATERIAL AND METHODS: Between 1994 and 2004, 17 patients were treated with HDR BRT for inoperable GBM. Of those, only 11 patients were treated with IRT BRT, and the remaining six patients received combined IRT BRT and external beam radiotherapy (EBRT). Patient’s median age was 59.3 years (range, 29-83 years) and median tumor volume was 39.3 cm(3) (range, 2-162 cm(3)). The prescribed HDR dose was median 40 Gy (range, 30-40 Gy), delivered twice daily in 5.0 Gy fractions over four consecutive days. Survival from BRT, toxicity as well as the impact of several prognostic factors was evaluated. RESULTS: At a median follow-up of 9.3 months, the median overall survival for the whole population, after BRT alone, and combined BRT with EBRT was 9.3, 7.3, and 10.1 months, respectively. Of the prognostic variables evaluated in univariate analysis, i.e., age, Karnofsky performance score, BRT dose, and tumor volume, only the latter one reached statistical significance. Two patients (11.7%) developed treatment-associated adverse events, with one (5.8%) symptomatic radionecrosis and one (5.8%) severe convulsion episode, respectively. CONCLUSIONS: For patients with inoperable GBM, IRT HDR BRT alone or in combination with EBRT is a safe and effective irradiation method providing palliation without excessive toxicity. Termedia Publishing House 2019-06-28 2019-06 /pmc/articles/PMC6701379/ /pubmed/31435428 http://dx.doi.org/10.5114/jcb.2019.85722 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Chatzikonstantinou, Georgios
Ulrich, Peter
Archavlis, Eleftherios
Zamboglou, Nikolaos
Strouthos, Iosif
Zoga, Eleni
Baltas, Dimos
Tselis, Nikolaos
Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title_full Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title_fullStr Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title_full_unstemmed Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title_short Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
title_sort interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701379/
https://www.ncbi.nlm.nih.gov/pubmed/31435428
http://dx.doi.org/10.5114/jcb.2019.85722
work_keys_str_mv AT chatzikonstantinougeorgios interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT ulrichpeter interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT archavliseleftherios interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT zamboglounikolaos interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT strouthosiosif interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT zogaeleni interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT baltasdimos interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme
AT tselisnikolaos interstitialhighdoseratebrachytherapyintheprimarytreatmentofinoperableglioblastomamultiforme